Not finding it? Sign in to also search OpenAlex live.
-
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
208P Clinical importance of residual axillary disease following neoadjuvant systemic therapy as an indicator for adjuvant systemic therapy in HER2+ and triple-negative breast cancer2025 ESMO Open article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Eva L. Claassens, Linetta B. Koppert, Carmen C. van der Pol, Ernest J. T. Luiten, Thiemo J. A. van Nijnatten, Janine M. Simons, +1 more
0citations -
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial2020 International Journal of Radiation Oncology*Biology*Physics article Medicine Endometrial and Cervical Cancer Treatments Open access
Cathalijne Post, Stephanie M. de Boer, Melanie E. B. Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, +24 more
47citations -
Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy2025 Journal of the European Academy of Dermatology and Venereology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Katharina Schumann, Kai Christian Klespe, Cornelia Mauch, Carmen Loquai, Ulrike Schultheis, Sevil Börger, +20 more
1citations -
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy2020 International Journal of Gynecological Cancer article Medicine Endometrial and Cervical Cancer Treatments Open access
Anne Sophie V M van den Heerik, Nanda Horeweg, Stephanie M. de Boer, Tjalling Bosse, Carien L. Creutzberg
198citations -
Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer2026 European Journal of Surgical Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Eva L. Claassens, Linetta B. Koppert, Carmen C. van der Pol, Ernest J. T. Luiten, Thiemo J. A. van Nijnatten, Agnes Jager, +18 more
0citations -
Adjuvant Transgingival Therapy with Visible Light Plus Water-Filtered Infrared-A (VIS + wIRA) in Periodontal Therapy—A Randomized, Controlled, Stratified, Double-Blinded Clinical Trial
Stefanie Anna Peikert, Anil Fischer, Anne Kruse, Ali Al‐Ahmad, Johan Peter Woelber, Kirstin Vach, +2 more
2citations -
Abstract PS3-08-14: Typer—A randomized controlled trial evaluating the effect of typology-based coaching on therapy management for patients with hr+/her2- early breast cancer under adjuvant ribociclib treatment
M.K. Welslau, Christine Zeder-Göß, Renate Haidinger, Brigitte Welter, B. Aktas, P. Wimberger, +14 more
0citations -
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.2023 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Irene L. M. Reijers, Alexander Maxwell Menzies, Judith M. Versluis, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, +14 more
10citations -
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis2023 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Melissa Melanie de Meza, Willeke A.M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, +14 more
16citations -
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial2023 EClinicalMedicine article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Vivianne C. G. Tjan‐Heijnen, Senna W. M. Lammers, Sandra M. E. Geurts, Ingeborg J. H. Vriens, Astrid C P Swinkels, Carolien H. Smorenburg, +8 more
16citations -
The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma2020 Cancer Immunology Immunotherapy article Medicine Cancer Immunotherapy and Biomarkers Open access
Daniëlle Krijgsman, Natasja L. De Vries, Morten Nørgaard Andersen, Anni Skovbo, Rob A.�E.�M. Tollenaar, Esther Bastiaannet, +2 more
15citations -
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.2020 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Christian U. Blank, Irene L. M. Reijers, Thomas E. Pennington, Judith M. Versluis, Robyn P.M. Saw, Elisa A. Rozeman, +14 more
62citations -
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L. M. Reijers, Alexander Maxwell Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, N.M.J. Van Den Heuvel, Robyn P.M. Saw, +31 more
378citations -
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.2022 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Christian U. Blank, Irene L. M. Reijers, Robyn P.M. Saw, Judith M. Versluis, Thomas E. Pennington, Ellen Kapiteijn, +14 more
17citations -
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial
Sonja B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg, Annelot G.J. van Rossum, Vincent Olaf Dezentjé, Agnes Jager, +12 more
21citations -
Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy
Liesbeth M. Hondelink, Sophie M. Ernst, Peggy N. Atmodimedjo, Danielle B. Cohen, Janina L Wolf, Anne‐Marie C. Dingemans, +2 more
33citations -
Side-effects in women treated with adjuvant endocrine therapy for breast cancer2025 The Breast article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Roxanne Gal, Anne Maria May, Marilot C. T. Batenburg, Femke van der Leij, Rhodé M. Bijlsma, Helena Marieke Verkooijen, +5 more
12citations -
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials2020 Critical Reviews in Oncology/Hematology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
Ali Belkouz, Johanna W. Wilmink, Nadia Haj Mohammad, Jeroen Hagendoorn, Judith de Vos‐Geelen, C.H.C. Dejong, +6 more
18citations